The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 22, 2023

Filed:

Apr. 02, 2020
Applicants:

Hoffmann-la Roche Inc., Nutley, NJ (US);

Ludwig-maximilians-universitat Munchen, Munich, DE;

Inventors:

Carole Bourquin, Belfaux, CH;

Raffaella Castoldi, Munich, DE;

Stefan Endres, Munich, DE;

Christian Klein, Bonstetten, CH;

Sebastian Kobold, Munich, DE;

Gerhard Niederfellner, Oberhausen, DE;

Claudio Sustmann, Munich, DE;

Assignee:

Other;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/30 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 16/32 (2006.01);
U.S. Cl.
CPC ...
C07K 16/30 (2013.01); A61K 39/001102 (2018.08); A61K 39/39558 (2013.01); C07K 16/2863 (2013.01); C07K 16/32 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/31 (2013.01); Y02P 20/582 (2015.11);
Abstract

Provided is a bispecific (monoclonal) antibody molecule with a first binding domain binding an antigen on CD8+ T-cells that does not naturally occur in and/or on CD8+ T-cells and a second binding domain binding to a tumor specific antigen naturally occurring on the surface of a tumor cell. The bispecific (monoclonal) antibody molecules are particularly useful in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8T-cells and/or a T-cell receptor. The (bispecific) antibody molecules can be used in a method for the treatment of particular diseases, wherein the (bispecific) antibody molecules are administered in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor in a specific treatment regimen.


Find Patent Forward Citations

Loading…